



Dr. rer. nat. Marianne Kraus

Contact

Dr. rer. nat. Marianne Kraus
Switzerland

marianne.kraus@kssg.ch

Units

Medizinische Onkologie und Hämatologie

Publications (32)

Besse A, Sedlarikova L, Büchler L, Kraus M, Yang C, Strakova N, Soucek K, Navratil J, Svoboda M, Welm A, Jörger M, Driessen C, Besse L. HIV-protease inhibitors potentiate the activity of carfilzomib in triple-negative breast cancer. *Br J Cancer* 2024

Besse L, Kraus M, Besse A, Driessen C, Tarantino I. The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma. *Sci Rep* 2023; 13:4411.

Besse L, Besse A, Kraus M, Maurits E, Overkleeft H, Bornhauser B, Bourquin J, Driessen C. High Immunoproteasome Activity and sXBP1 in Pediatric Precursor B-ALL Predicts Sensitivity towards Proteasome Inhibitors. *Cells* 2021; 10

Byrgazov K, Besse A, Kraus M, Slipicevic A, Lehmann F, Driessen C, Besse L. Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells. *Hemasphere* 2021; 5:e602.

Byrgazov K, Kraus M, Besse A, Slipicevic A, Lehmann F, Driessen C, Besse L. Up-regulation of multidrug resistance protein MDR1/ABCB1 in carfilzomib-resistant multiple myeloma differentially affects efficacy of anti-myeloma drugs. *Leuk Res* 2020; 101:106499.

Hitz F, Driessen C, Mey U, Samaras P, Vilei S, Stüdeli S, Rondeau S, Seipel K, Novak U, Silzle T, Besse L, Hess D, Pabst T, Kraus M, Swiss Group for Clinical Cancer Research SAKK. Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10). *Blood Cancer J* 2019; 9:70.

Brünnert D, Kraus M, Stühmer T, Kirner S, Heiden R, Goyal P, Driessen C, Bargou R, Chatterjee M. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma. *Biochim Biophys Acta Mol Basis Dis* 2019; 1865:1666-1676.

Skrott Z, Pouckova P, Sedlacek J, Miklovicova A, Kutt A, Li J, Mattova J, Driessen C, Dou Q, Olsen J, Hajdich M, Cvek B, Deshaies R, Vrobel I, Dzubak P, Mistrik M, Andersen K, Friis S, Majera D, Gursky J, Ozdian T, Bartkova J, Turi Z, Moudry P, Kraus M, Michalova M, Vaclavkova J, Bartek J. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. *Nature* 2017; 552:194-199.

Abt D, Driessen C, Engeler D, Schmid H, Slaby O, Vodinska M, Silzle T, Bader J, Kraus M, Sedlarikova L, Besse A, Besse L. Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir. *BJU Int* 2017

Le Moigne R, Chesi M, Bergsagel P, Kraus M, Driessen C, Kiss von Soly S, Yakes F, Wustrow D, Shawver L, Zhou H, Martin T, Wolf J, Mitsiades C, Anderson D, Wang J, Rice J, Lam C, Aftab B, Djakovic S, Dhimolea E, Valle E, Murnane M, King E, Soriano F, Menon M, Wu Z, Wong S, Lee G, Yao B, Wiita A, Rolfe M. The p97 Inhibitor CB-5083 Is a Unique Disrupter of Protein Homeostasis in Models of Multiple Myeloma. *Mol Cancer Ther* 2017; 16:2375-2386.

Besse L, Kraus M, Besse A, Bader J, Silzle T, Mehrling T, Driessen C. The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways. *Blood Cancer J* 2017; 7:e589.

Besse A, Besse L, Overkleeft H, Bader J, Kraus M, Morgan G, Weinhold N, Rasche L, Stolze S, Driessen C. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma. *Leukemia* 2017; 32:391-401.

Soriano G, Florea B, Overkleeft H, den Dulk H, Everts B, Bader J, Meeuwenoord N, Besse A, Kraus M, Li N, Besse L, Driessen C. Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism. *Leukemia* 2016; 30:2198-2207.

Driessen C, Hess D, von Moos R, Pabst T, Huitema A, Sessa C, Overkleeft H, Berthod G, Hawle H, Xyrafas A, Berset C, Hitz F, Bader J, Rosing H, Jörgen M, Kraus M, Mey U. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08). *Haematologica* 2015; 101:346-55.

de Bruin G, Xin B, Kraus M, van der Stelt M, van der Marel G, Kisselev A, Driessen C, Florea B, Overkleeft H. A Set of Activity-Based Probes to Visualize Human (Immuno)proteasome Activities. *Angew Chem Int Ed Engl* 2015; 55:4199-203.

Kraus J, Kraus M, Liu N, Besse L, Bader J, Geurink P, de Bruin G, Kisselev A, Overkleeft H, Driessen C. The novel β 2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells. *Cancer Chemother Pharmacol* 2015; 76:383-96.

Kraus M, Overkleeft H, Kisselev A, Li N, Appenzeller C, van Rooden E, Haile S, de Bruin G, van der Linden W, Shabaneh T, Silzle T, Mirabella A, Weyburne E, Geurink P, Bader J, Driessen C. The novel β 2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells. *Haematologica* 2015; 100:1350-60.

Kraus M, Müller-Ide H, Rückrich T, Bader J, Overkleeft H, Driessen C. Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations. *Leuk Res* 2013; 38:383-92.

Auner H, Karadimitris A, Apperley J, Rahemtulla A, Dazzi F, Cenci S, Driessen C, Chaidos A, May P, Milan E, Kraus M, Ward T, Moody A, Dillon N. Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells. *PloS one* 2013; 8:e74415.

Kraus M, Bader J, Overkleeft H, Driessen C. Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance. *Blood Cancer J* 2013; 3:e103.

Clerc J, Overkleeft H, Driessen C, Dudler R, Bachmann A, Huber R, Groll M, Kraus M, Florea B, Kaiser M. Syringolin A selectively labels the 20 S proteasome in murine EL4 and wild-type and bortezomib-adapted leukaemic cell lines. *Chembiochem : a European journal of chemical biology* 2009; 10:2638-43.

Harman A, Driessen C, Slobedman B, Stern J, Nasr N, Mercier S, Tang O, Turville S, Byth K, Bye C, Kraus M, Cunningham A. HIV-1-infected dendritic cells show 2 phases of gene expression changes, with lysosomal enzyme activity decreased during the second phase. *Blood* 2009; 114:85-94.

Rückrich T, Kraus M, Gogel J, Beck A, Ovaa H, Verdoes M, Overkleeft H, Kalbacher H, Driessen C. Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells. *Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K* 2009; 23:1098-105.

Fissolo N, Kraus M, Reich M, Ayturan M, Overkleeft H, Driessen C, Weissert R. Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation. *European journal of immunology* 2008; 38:2401-11.

Kraus M, Hartmann J, Koscielniak E, Ovaa H, Overkleeft H, Rückrich T, Müller H, Gogel J, Malenke E, Driessen C. Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis. *Molecular cancer therapeutics* 2008; 7:1940-8.

Busse A, Kraus M, Na I, Rietz A, Scheibenbogen C, Driessen C, Blau I, Thiel E, Keilholz U. Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits. *Cancer* 2008; 112:659-70.

Reich M, van Swieten P, Sommandas V, Kraus M, Fischer R, Weber E, Kalbacher H, Overkleeft H, Driessen C. Endocytosis targets exogenous material selectively to cathepsin S in live human dendritic cells, while cell-penetrating peptides mediate nonselective transport to cysteine cathepsins. *Journal of leukocyte biology* 2007; 81:990-1001.

Kraus M, Ovaa H, Overkleeft H, Burg D, Berkers C, Kammer W, Beck A, Gogel J, Reich M, Rückrich T, Driessen C. Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells. *Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K* 2007; 21:84-92.

Burster T, Overkleeft H, Weber E, Häring H, Kalbacher H, Kraus M, Reich M, Weissert R, Schnorrer P, Tolosa E, Beck A, Driessen C. Differential processing of autoantigens in lysosomes from human monocyte-derived and peripheral blood dendritic cells. *Journal of immunology (Baltimore, Md. : 1950)* 2005; 175:5940-9.

van Zutphen S, Kraus M, Driessen C, van der Marel G, Overkleeft H, Reedijk J. Probing the potential of platinum(II) complexes for the inhibition of thiol-dependent enzymatic activity. *Journal of inorganic biochemistry* 2005; 99:1384-9.

Dengjel J, Rammensee H, Driessen C, Brock R, Kalbacher H, Brandenburg J, Altenberend F, Kreymborg K, Müller M, Kraus M, Reich M, Fischer R, Schoor O, Stevanovic S. Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. *Proceedings of the National Academy of Sciences of the United States of America* 2005; 102:7922-7.

Lautwein A, Nordheim A, Kalbacher H, Weber E, Kammer W, Schwarz G, Overkleeft H, Brandenburg J, Burster T, Reich M, Kraus M, Driessen C. Human B lymphoblastoid cells contain distinct patterns of cathepsin activity in endocytic compartments and regulate MHC class II transport in a cathepsin S-independent manner. *Journal of leukocyte biology* 2004; 75:844-55.

Projects (11)

ALK-Inhibitoren als potentielle Therapie bei Proteasom-Inhibitor-resistentem Multiplen Myelom

Fundamental Research - Oct 1, 2021 - Sep 30, 2023

Automatically Closed

Immunoproteasome activity as a predictive marker and therapeutic target in hematological malignancies

Fundamental Research - Jul 1, 2021 - Dec 31, 2021

Automatically Closed

The molecular landscape of proteasome inhibitor resistance of multiple myeloma in vivo

Fundamental Research - Jul 1, 2020 - Dec 31, 2023

Automatically Closed

Identifying and targeting the "Achilles' heel" in proteasome inhibitor-resistant multiple myeloma

Fundamental Research - Oct 1, 2018 - Dec 31, 2021

Automatically Closed

HIV-Proteaseinhibitoren als Basis für Krebstherapie: Verständnis des Mechanismus, Identifikation der Targets, Entwicklung wirksamerer Substanzen

Fundamental Research - Nov 1, 2016 - Oct 31, 2018

Automatically Closed

Improving the activity of proteasome inhibitors for potential treatment of

Fundamental Research - Mar 31, 2015 - Dec 7, 2018

Automatically Closed

Development and preclinical characterization of third-generation proteasome inhibitors

Clinical Studies - Jan 1, 2013 - Dec 31, 2015

Automatically Closed

In vitro proteotoxic synergism of nelfinavir and carfilzomib in solid cancer cell lines

Fundamental Research - Jan 1, 2013 - Dec 31, 2014

Automatically Closed

Präklinische Charakterisierung neuer Einsatzmöglichkeiten von Proteasominhibitoren zur Vorbereitung innovativer klinischer Investigator-initiiertes Studien in der Onkologie

Fundamental Research - Jul 1, 2012 - Jun 30, 2013

Automatically Closed

Development of third-generation proteasome inhibitors for clinical applications

Clinical Studies - Jan 1, 2012 - Dec 31, 2012

Automatically Closed

In vitro Untersuchung der Proteasen-Aktivität und der Wirkung von Proteasen-Inhibitoren bei hämatologischen Neoplasien

Clinical Studies - May 18, 2009 - May 18, 2020

Automatically Closed

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch